AUSTIN, Texas, Oct. 7 /PRNewswire/ -- DiFUSION Technologies is a medical device company focused on the development and commercialization of its proprietary CleanFUZE™ antimicrobial technology for orthopedic implants and its new Xiphos™ line of Posterior Interbody products for spinal surgery.
"Post-operative infections are a major problem today, and with the further proliferation of drug resistant bacteria, preventing the infections is even more important than it has been in the past. Having materials that actively fight against post-operative infections is an important step towards eliminating this devastating problem," said Dr. Nitin N. Bhatia, MD, Chief, Spine Service Co-Director, Combined Spine Program, Residency Program Director Dept. of Orthopedic Surgery, University of California, Irvine.
DiFUSION's recently completed third party animal tests showed that after introducing Methicillin Resistant Staphylococcus Aureus (MRSA), a common, aggressive, multi-drug resistant bacterium, to rabbits implanted with DiFUSION's proprietary CleanFUZE orthobiologic polymer, the animals showed little visible inflammation or infection. Microscopic analysis of the same samples showed CleanFUZE to be up to 99.99% effective in eradicating the active infection.
"This is the first time any potential biomaterial has shown, in an animal model, to significantly reduce the numbers of an infectious agent as well as the local tissue markers of actual infection," said Matthew Geck, MD, cofounder of DiFUSION. "This was done using a safe and tissue friendly, pharmacologic dosing of silver with our innovative and proprietary biomaterial that combines the structural properties of PEEK with the controlled elution of cationic silver. This biomaterial has the potential to be the base material for a whole range of spine and orthopedic implants."
According to a variety of large published studies, post-operative surgical site infections (SSIs) occur in
|SOURCE DiFUSION Technologies, Inc.|
Copyright©2010 PR Newswire.
All rights reserved